These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

900 related articles for article (PubMed ID: 30684797)

  • 1. Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents - A recent update.
    Jain PG; Patel BD
    Eur J Med Chem; 2019 Mar; 165():198-215. PubMed ID: 30684797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
    Henning RJ; Bourgeois M; Harbison RD
    Cardiovasc Toxicol; 2018 Dec; 18(6):493-506. PubMed ID: 29968072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Common and unique genetic interactions of the poly(ADP-ribose) polymerases PARP1 and PARP2 with DNA double-strand break repair pathways.
    Ghosh R; Roy S; Kamyab J; Danzter F; Franco S
    DNA Repair (Amst); 2016 Sep; 45():56-62. PubMed ID: 27373144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors.
    Hopkins TA; Shi Y; Rodriguez LE; Solomon LR; Donawho CK; DiGiammarino EL; Panchal SC; Wilsbacher JL; Gao W; Olson AM; Stolarik DF; Osterling DJ; Johnson EF; Maag D
    Mol Cancer Res; 2015 Nov; 13(11):1465-77. PubMed ID: 26217019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The ups and downs of Poly(ADP-ribose) Polymerase-1 inhibitors in cancer therapy-Current progress and future direction.
    Zhao Y; Zhang LX; Jiang T; Long J; Ma ZY; Lu AP; Cheng Y; Cao DS
    Eur J Med Chem; 2020 Oct; 203():112570. PubMed ID: 32717529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Review on Poly (ADP-ribose) Polymerase (PARP) Inhibitors and Synthetic Methodologies.
    Li Y; Liu CF; Rao GW
    Curr Med Chem; 2021; 28(8):1565-1584. PubMed ID: 32164505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteomic Analysis of the Downstream Signaling Network of PARP1.
    Zhen Y; Yu Y
    Biochemistry; 2018 Jan; 57(4):429-440. PubMed ID: 29327913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond.
    Boussios S; Abson C; Moschetta M; Rassy E; Karathanasi A; Bhat T; Ghumman F; Sheriff M; Pavlidis N
    Drugs R D; 2020 Jun; 20(2):55-73. PubMed ID: 32215876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Veliparib: a new therapeutic option in ovarian cancer?
    Ghisoni E; Giannone G; Tuninetti V; Genta S; Scotto G; Aglietta M; Sangiolo D; Mittica G; Valabrega G
    Future Oncol; 2019 Jun; 15(17):1975-1987. PubMed ID: 31074636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The dynamics and regulation of PARP1 and PARP2 in response to DNA damage and during replication.
    Zhang H; Zha S
    DNA Repair (Amst); 2024 Aug; 140():103690. PubMed ID: 38823186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
    Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
    Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dissecting the molecular determinants of clinical PARP1 inhibitor selectivity for tankyrase1.
    Ryan K; Bolaňos B; Smith M; Palde PB; Cuenca PD; VanArsdale TL; Niessen S; Zhang L; Behenna D; Ornelas MA; Tran KT; Kaiser S; Lum L; Stewart A; Gajiwala KS
    J Biol Chem; 2021; 296():100251. PubMed ID: 33361107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Revisiting PARP2 and PARP1 trapping through quantitative live-cell imaging.
    Zhang H; Lin X; Zha S
    Biochem Soc Trans; 2022 Aug; 50(4):1169-1177. PubMed ID: 35959996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone ADP-ribosylation promotes resistance to PARP inhibitors by facilitating PARP1 release from DNA lesions.
    Zentout S; Imburchia V; Chapuis C; Duma L; Schützenhofer K; Prokhorova E; Ahel I; Smith R; Huet S
    Proc Natl Acad Sci U S A; 2024 Jun; 121(25):e2322689121. PubMed ID: 38865276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Poly(ADP-Ribose) Polymerases 1 and 2: Classical Functions and Interaction with New Histone Poly(ADP-Ribosyl)ation Factor HPF1].
    Kurgina TA; Lavrik OI
    Mol Biol (Mosk); 2023; 57(2):254-268. PubMed ID: 37000654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PARP1: A Promising Target for the Development of PARP1-based Candidates for Anticancer Intervention.
    Zhu X; Ma X; Hu Y
    Curr Med Chem; 2016; 23(17):1756-74. PubMed ID: 25245372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphatase 1 Nuclear Targeting Subunit Mediates Recruitment and Function of Poly (ADP-Ribose) Polymerase 1 in DNA Repair.
    Wang F; Zhu S; Fisher LA; Wang L; Eurek NJ; Wahl JK; Lan L; Peng A
    Cancer Res; 2019 May; 79(10):2526-2535. PubMed ID: 30733193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identifying new piperazine-based PARP1 inhibitors using text mining and integrated molecular modeling approaches.
    Sahin K; Durdagi S
    J Biomol Struct Dyn; 2021 Feb; 39(2):681-690. PubMed ID: 32048546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serine-linked PARP1 auto-modification controls PARP inhibitor response.
    Prokhorova E; Zobel F; Smith R; Zentout S; Gibbs-Seymour I; Schützenhofer K; Peters A; Groslambert J; Zorzini V; Agnew T; Brognard J; Nielsen ML; Ahel D; Huet S; Suskiewicz MJ; Ahel I
    Nat Commun; 2021 Jul; 12(1):4055. PubMed ID: 34210965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery, mechanism and metabolism studies of 2,3-difluorophenyl-linker-containing PARP1 inhibitors with enhanced in vivo efficacy for cancer therapy.
    Chen W; Guo N; Qi M; Dai H; Hong M; Guan L; Huan X; Song S; He J; Wang Y; Xi Y; Yang X; Shen Y; Su Y; Sun Y; Gao Y; Chen Y; Ding J; Tang Y; Ren G; Miao Z; Li J
    Eur J Med Chem; 2017 Sep; 138():514-531. PubMed ID: 28692916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.